Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Athersys (ATHX) plans for P2 stroke clinical trial

ATHX plans for a P2 ischemic stroke clinical trial that’s estimated to involve about 140 patients

The double-blind, randomized, placebo-controlled study is designed to evaluate the safety and effectiveness of treating stroke patients with MultiStem, an off-the-shelf stem cell treatment derived from the bone marrow of adults or other non-embryonic sources.

  • The trial is scheduled to start enrollment this month, with 10/13 estimated as the time frame for final data collection and is expected to be completed by 11/14.

The Bottom Line: ATHX believes MultiStem could represent a significant advancement in treating ischemic stroke patients. The technology has shown promise in reducing inflammation, protecting damaged tissue and forming new blood vessels. Ischemic stroke is caused by a blood clot in the brain and accounts for 87% of all stroke cases.

Stroke is the most promising application of MultiStem which is also being investigated for the treatment of heart attack, inflammatory bowel disease, orthopedics and blood diseases.